

Falsely Elevated Serum Vitamin B₁₂ Levels Were Associated with the Severity and Prognosis of Chronic Viral Liver Disease

Takaaki Sugihara, Masahiko Koda, Toshiaki Okamoto, Kenichi Miyoshi, Tomomitsu Matono, Kenji Oyama, Keiko Hoshino, Jun-ichi Okano, Hajime Isomoto and Yoshikazu Murawaki

Division of Medicine and Clinical Science, Department of Multidisciplinary Internal Medicine, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8504, Japan

ABSTRACT

Background Vitamin B₁₂ is stored primarily in the liver, and highly elevated serum vitamin B₁₂ levels occur in acute hepatitis and severe alcoholic liver disease. We evaluated the relationship between vitamin B₁₂ levels and liver disease severity and long term prognosis in patients with chronic viral hepatitis and cirrhosis.

Methods We enrolled 90 patients (57 men, 33 women) with chronic viral hepatitis and cirrhosis who admitted to our hospital as a prospective cohort study. Overall, 37 patients had chronic hepatitis and 53 had cirrhosis (Child-Pugh A 33, B 13, and C 7); 57 patients had primary liver cancer. Serum vitamin B₁₂ concentration and holotranscobalamin (holoTC) II (active form of vitamin B₁₂) were determined and followed prospectively for at least 5 years.

Results Mean total serum vitamin B₁₂ concentration was significantly higher in Child-Pugh C (1308 ± 599 pg/mL) compared to those with chronic hepatitis (655 ± 551 pg/mL), Child-Pugh A (784 ± 559 pg/mL), and Child-Pugh B (660 ± 464 pg/mL) ($P = 0.036$). Presence of primary liver cancer also influenced serum vitamin B₁₂ levels [657 (167–2956) vs. 432 (189–2956); $P = 0.015$]. Patients were divided into quartiles by vitamin B₁₂ level. Patients without primary liver cancer in quartile 4 (≥ 880 pg/mL) demonstrated significantly poorer prognosis than those in quartiles 1–3 (< 880 pg/mL) ($P = 0.023$). The percentage of holohaptocorrin (holoHC) [(total vitamin B₁₂ – holoTC II) × 100] was significantly higher in Child-Pugh B and C 86 (80–87)% than chronic hepatitis and Child-Pugh A 77 (31–89)% ($P = 0.006$). Multivariate analysis indicated serum vitamin B₁₂ levels (HR = 1.001, $P = 0.029$) as a prognostic factor.

Conclusion Falsely elevated serum vitamin B₁₂ levels mainly composed of increased holoHC were associated with severity (Child-Pugh C and primary liver cancer) and prognosis in chronic viral liver disease.

Key words holotranscobalamin; liver cirrhosis; prognosis; viral hepatitis; vitamin B₁₂

Vitamin B₁₂ is stored primarily in the liver; this vitamin is essential for one-carbon metabolism and cell division. It acts as a cofactor for two enzymatic reactions, namely, methionine synthesis from homocysteine and succinyl-CoA synthesis from methylmalonyl-CoA, in mammalian systems.¹ Some studies have indicated that elevated serum levels of vitamin B₁₂ might be a sign of a serious and life-threatening disease. Such falsely high values of serum vitamin B₁₂ levels are observed in myeloproliferative disease, acute hepatitis, severe alcoholic liver disease, and cirrhosis.^{2–6}

Vitamin B₁₂ binds with transcobalamin (TC) II. The complex holoTC II, which is the biologically active form of vitamin B₁₂, is recognized by specific receptors on all cell types. The active form of vitamin B₁₂ comprises only 6–20% of the total serum vitamin B₁₂ level. The remaining major portion (70–90%) is bound to haptocorrin (HC); this is named holohaptocorrin (holoHC) and is the inactive form of vitamin B₁₂, which is stored in the liver.^{7,8} Several reports have reported that the falsely high values are due to increasing the holoHC levels.³

In our experience, we have observed highly elevated vitamin B₁₂ levels in patients with advanced stages of viral liver cirrhosis. There are only one report that demonstrated the association of vitamin B₁₂ level with disease severity and mortality in hepatitis B virus infection with short term.⁹ No reports have evaluated the dynamics of vitamin B₁₂ in chronic viral hepatitis. Accordingly, the present study aimed to evaluate the relationship of serum vitamin B₁₂ between the disease severity and long term prognosis of liver disease in patients with viral hepatitis and cirrhosis.

Corresponding author: Takaaki Sugihara, MD, PhD

sugitaka@med.tottori-u.ac.jp

Received 2016 December 8

Accepted 2017 January 4

Abbreviations: AFP, alpha-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CD, cluster of differentiation; DCP, des- γ -carboxy prothrombin; HBV, hepatitis B virus; HC, haptocorrin; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; holoHC, holohaptocorrin; holoTC, holotranscobalamin; HR, hazard ratio; NF κ B, nuclear factor kappa B; NK, natural killer; TC, transcobalamin; TNF- α , tumor necrosis factor-alpha; TNM, TNM classification of malignant tumours

SUBJECTS AND METHODS

Subjects

From March 2007 to March 2010, consecutive patients with chronic viral hepatitis and viral induced cirrhosis were prospectively enrolled in the present study. Patients who underwent a total gastrectomy, vegetarians and those receiving nutrient supplementation, including vitamin B₁₂, were excluded from the study.

Methods

Cirrhosis was diagnosed according to clinical, biochemical, and/or imaging findings. The severity of cirrhosis was categorized using the Child-Pugh classification.¹⁰ The presence of primary liver cancer was also recorded. The stages of hepatocellular carcinoma (HCC) were categorized by TNM staging. Blood samples were collected at the date of inclusion, and hemoglobin, blood chemistry [albumin, total bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT)], prothrombin activity percentage, alpha-fetoprotein (AFP), and des-γ-carboxy prothrombin (DCP), and serum vitamin B₁₂ levels were determined. Total serum vitamin B₁₂ concentration was determined by chemiluminescent immunoassay (CLIA: Access Vitamin B₁₂; beckman coulter, Tokyo, Japan). Levels of holoTC II were also measured by microparticle enzyme immunoassay (AxSYM Active-B₁₂; abbott diagnostics, Abbott Park, IL). The percentage of holoTC II was expressed as the ratio of holoTC II to total serum vitamin B₁₂. The percentage of holoHC was calculated as (total vitamin B₁₂ – holoTC II) × 100. All the patients were followed prospectively for at least 5 years and evaluated for prognosis.

Ethical Considerations

The study protocol confirmed to the ethical guidelines of the Helsinki Declaration of 1975, as revised in 2000, and was approved by the ethics committee of the Tottori University (No. 1231). Patients were enrolled after giving their written informed consent.

Statistical analysis

Data are expressed as median (range) or mean ± SD. Statistical analyses for significant differences among the groups were performed using the chi-square test, Student's *t* test, Mann-Whitney's *U* test, ANOVA, and Kruskal-Wallis Test. *F* test and Bartlett's test was used to assess the equality of variances. Correlations were calculated using Pearson's product-moment correlation coefficient. Cumulative survival rate was calculated by the Kaplan-Meier method, and significant differences between two groups were calculated using the Log rank test. Multivariate analyses were performed using the

Cox proportional hazards model. Statistical significance was set at $P < 0.05$.

RESULTS

Patient background

Ninety patients [57 men, 33 women; median age, 69 (range, 30–88) years] were enrolled this study. Of these patients, 60 (67%) had hepatitis C virus (HCV) and 30 patients (33%) had hepatitis B virus (HBV). Twenty patients (22%) habitually consumed ≥ 20 g/day alcohol. Seven patients (8%) had heart disease (e.g. ischemic heart disease, valvular heart disease, and arrhythmia). Nine patients (10%) underwent distal gastrectomy. Underlying liver disease was chronic hepatitis in 37 patients (41%) and cirrhosis in 53 (59%) (Table 1).

Table 1. Clinical findings in study subjects

Patients	<i>n</i> = 90	
Sex (Male:Female)	57:33	
Age (years)	69 (30–88)	
Etiology		
HBV infection	30 (33%)	
HCV infection	60 (67%)	
Alcohol consumption (≥ 20 g/day)	20 (22%)	
Comorbidity		
Heart disease	7 (8%)	
Gastrectomy (distal)	9 (10%)	
Atrophic gastritis	33 (37%)	
The severity of underlying liver disease		
Chronic hepatitis	37 (41%)	
Cirrhosis	53 (59%)	
Child-Pugh classification		
(A:B:C)	33:13:7	
Primary Liver Cancer (HCC:ICC)	56:1 (62%)	
TNM Stage		
(I:II:III:IV:unknown)	18:11:17:4:5:2	
Laboratory values		
Hemoglobin	(g/dL)	12.3 (6.5–16.9)
MCV	(fL)	95.8 (62.4–112.9)
MCHC	(%)	34.4 (31.4–36)
Albumin	(g/dL)	3.6 (2.1–5.1)
AST	(IU/L)	47 (14–847)
ALT	(IU/L)	37 (7–1073)
Total bililubin	(mg/mL)	0.8 (0.3–15.1)
Prothrombin percent activity	(%)	86.9 (5–117.1)
Total serum vitamin B ₁₂	(pg/mL)	584.5 (160–2956)
AFP	(ng/mL)	8.7 (1.2–501570)
DCP	(mAU/mL)	24 (10–84980)

Data are expressed as median (range).

AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, alpha fetoprotein; DCP, Des-gamma-carboxy prothrombin; HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; ICC, intrahepatic cholangiocellular carcinoma; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; TNM, TNM classification of malignant tumours.

Vitamin B₁₂ analysis

Serum vitamin B₁₂ levels were significantly higher in patients with cirrhosis than chronic hepatitis [647 (160–2956) vs. 461 (189–2956) pg/mL (*P* = 0.029)], and it was particularly in patients categorized as Child-Pugh C (1308 ± 599 pg/mL) than those with chronic hepatitis (655 ± 551pg/mL), Child-Pugh A (784 ± 559 pg/mL), and Child-Pugh B (660 ± 464 pg/mL) (*P* = 0.036) (Fig.1). The vitamin B₁₂ levels were also higher in patients with primary liver cancer than those without [657 (167–2956) vs. 432 (189–2956) pg/mL, *P* = 0.015] (Table 2).

Then we divided the patients with and without primary liver cancer. Among the patients with primary liver cancer, the vitamin B₁₂ levels were found to be significantly higher in drinkers (alcohol consumption ≥ 20 g/day) than non-drinkers [885 (160–2956) vs. 625 (263–2265) pg/mL, *P* = 0.025]. On the other hand, among the patients without primary liver cancer, it was significantly higher in patients with hepatitis B virus infection than hepatitis C virus infection [655 (272–2956) vs. 392 (189–1083) pg/mL, *P* = 0.018], and the patients with cirrhosis than chronic hepatitis [655 (379–2956) vs. 386 (189–1200) pg/mL, *P* = 0.004] (Table 3).

Moreover, we also divided the patients with chronic hepatitis and cirrhosis to separate the influence of liver function on vitamin B₁₂ for each parameter. Vitamin B₁₂ levels were significantly higher in primary liver cancer only in patients with chronic hepatitis [731 (196–2956) vs. 386 (189–1200) pg/mL, *P* = 0.009] (Table 4).

To evaluate the relationship of serum vitamin B₁₂ with the patients' clinical and biochemical parameters, the correlations between serum vitamin B₁₂ levels and those parameters (age, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, albumin, AST, ALT, total bilirubin, prothrombin activ-




Fig. 1. Serum vitamin B₁₂ levels in patients with chronic viral hepatitis. Serum vitamin B₁₂ levels were significantly higher in patients categorized as Child-Pugh C (1308 ± 599 pg/mL) than those in CH (655 ± 551 pg/mL), Child-Pugh A (784 ± 559 pg/mL), and Child-Pugh B (660 ± 464 pg/mL) (*P* = 0.036). **P* < 0.05. CH, chronic hepatitis.

ity percentage, AFP, and DCP) were estimated using Pearson's product-moment correlation coefficient. Serum vitamin B₁₂ levels were positively correlated with AFP (*r* = 0.231, *P* = 0.04), negatively prothrombin activity percentage (*r* = -0.248, *P* = 0.017) (Table 5).

Table 2. Influence of clinical factors on serum vitamin B₁₂ levels

		Serum vitamin B ₁₂ (pg/mL)	
		All patients (<i>n</i> = 90)	<i>P</i> value
Sex	(Male:Female)	581 (196–2956):640 (160–2956)	n.s.
Etiology	(HCV:HBV)	513 (189–2956):656 (160–2956)	n.s.
Alcohol ≥ 20g/day	(Yes:No)	660 (160–2956):520 (263–2265)	n.s.
Heart disease	(Yes:No)	431 (320–1298):410 (160–2956)	n.s.
Gastrectomy*	(Yes:No)	607 (160–2956):367 (263–1494)	n.s.
Cirrhosis	(Yes:No)	647 (160–2956):461 (189–2956)	0.029
Primary liver cancer	(Yes:No)	657 (160–2956):432 (189–2956)	0.015
TNM Stage	(I/II:III/IVA/IVB)	549 (233–2956):728 (160–2265)	n.s.

Data are expressed as median (range). *Distal gastrectomy.

HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, TNM classification of malignant tumours; n.s., not significant.

Table 3. Influence of clinical factors on serum vitamin B₁₂ levels between patients with and without primary liver cancer

	Serum vitamin B ₁₂ (pg/mL)		<i>P</i> value	Serum vitamin B ₁₂ (pg/mL)		<i>P</i> value
	Patients with primary liver cancer (<i>n</i> = 57)			Patients without primary liver cancer (<i>n</i> = 33)		
Sex (Male:Female)	632 (196–2956):686 (160–1957)		n.s.	461 (277–1200):410 (189–2956)		n.s.
Etiology (HCV:HBV)	664 (205–2956):657 (160–2029)		n.s.	392 (189–1083):655 (272–2956)		0.018
Alcohol ≥ 20 g/day (Yes:No)	885 (160–2956):625 (263–2265)		0.025	432 (299–1083):410 (189–2956)		n.s.
Heart disease (Yes:No)	819 (160–2956):647 (320–1298)		n.s.	581 (581–581):424 (189–2956)		n.s.
Gastrectomy* (Yes:No)	320 (263–1494):686 (160–2956)		n.s.	283 (367–379):461 (189–2956)		n.s.
Cirrhosis (Yes:No)	645 (160–2265):731 (196–2956)		n.s.	655 (379–2956):386 (189–1200)		0.004
TNM Stage (I/II:III/IVA/IVB)	549 (233–2956):728 (160–2265)		n.s.	—		—

Data are expressed as median (range). *Distal gastrectomy.

HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, TNM classification of malignant tumours; n.s., not significant.

Table 4. Influence of clinical factors on serum vitamin B₁₂ levels between patients with chronic hepatitis and cirrhosis

	Serum vitamin B ₁₂ (pg/mL)		<i>P</i> value	Serum vitamin B ₁₂ (pg/mL)		<i>P</i> value
	Patients with chronic hepatitis (<i>n</i> = 37)			Patients with cirrhosis (<i>n</i> = 53)		
Sex (Male:Female)	509 (196–2956):189 (189–1298)		n.s.	631 (205–2265):647 (160–2956)		n.s.
Etiology (HCV:HBV)	432 (189–2956):634 (196–1298)		n.s.	640 (205–2265):656 (160–2956)		n.s.
Alcohol ≥ 20 g/day (Yes:No)	461 (299–1298):449 (189–2956)		n.s.	1083 (263–2265):624 (160–2956)		n.s.
Heart disease (Yes:No)	634 (320–1298):432 (189–2956)		n.s.	952 (367–1292):645 (160–2956)		n.s.
Gastrectomy* (Yes:No)	344 (320–367):483 (189–2956)		n.s.	263 (160–2956):379 (263–1494)		n.s.
Primary liver cancer (Yes:No)	731 (196–2956):386 (189–1200)		0.009	645 (160–2265):655 (379–2956)		n.s.
TNM Stage (I/II:III/IVA/IVB)	526 (233–2956):731 (196–1417)		n.s.	751 (263–1957):472 (160–2965)		n.s.

Data are expressed as median (range). *Distal gastrectomy.

HBV, hepatitis B virus; HCV, hepatitis C virus; TNM, TNM classification of malignant tumours; n.s., not significant.

HoloTC II analysis

In 43 of 90 patients, levels of holoTC II were evaluated. We found that the percentage of holoTC II tended to decrease with progression of liver disease. The median percentages of holoTC II were 22(11–69)% in patients with chronic hepatitis (*n* = 25), 24 (19–37) % in Child-Pugh A (*n* = 13), 16 (13–20)% in Child-Pugh B (*n* = 4), and 13% in Child-Pugh C (*n* = 1), and the statistical significance was indicated between Child-Pugh A and B (*P* = 0.031) (Fig. 2A). The percentage of holoHC was

significantly higher in Child-Pugh B and C 86 (80–87)% compared with chronic hepatitis and Child-Pugh A 77 (31–89)% (*P* = 0.006) (Fig. 2B).

Survival analysis

During the observation period (median, 54.3 months; range, 0.6–101.7months), the overall survival rates were 89% at 1 year, 81% at 2 years, and 67% at 5 years. Cirrhotic patients had significantly poorer prognosis compared with non-cirrhotic patients [33.5 (0.6–101.7) vs.

66.9 (3.1–72.1) months, $P = 0.003$]. Patients with primary liver cancer had also significantly poorer prognosis compared to those without them [28.5 (0.6–101.7) vs. 67 (15.6–71.7) months, $P < 0.001$]. Ninety patients were divided into quartiles Q1 to Q4, according to serum vitamin B₁₂ level: Q1, < 403.25; Q2, 403.25–582; Q3, 583–879; and Q4, ≥ 880 pg/mL (Fig. 3A). Among all the patients, Q4 had markedly low cumulative survival

rate than those Q 1-3 ($P = 0.058$) (Fig. 3B). On the other hand, among the patients without primary liver cancer, Q4 had significantly low cumulative survival rate than Q 1-3 ($P = 0.003$) (Fig. 3C). Univariate analysis revealed that serum albumin, total bilirubin, AFP > 10 ng/mL, DCP > 40 AU/mL, and serum vitamin B₁₂ level were significant prognostic factors for the overall survival rate. The stepwise multivariate Cox proportional hazards model showed that the independent factors contributing to cumulative survival rate were serum albumin, DCP > 40 AU/mL and serum vitamin B₁₂ levels (Table 6).

Table 5. Correlations between serum vitamin B₁₂ levels and clinical/biochemical parameters

Patients ($n = 90$)	r	P value
Sex	-0.038	n.s.
Age (year)	-0.005	n.s.
Hemoglobin (g/dL)	-0.053	n.s.
MCV (fL)	-0.018	n.s.
MCHC (%)	0.001	n.s.
Albumin (g/dL)	-0.203	n.s.
AST (IU/L)	0.168	n.s.
ALT (IU/L)	0.114	n.s.
Total bilirubin (mg/mL)	0.113	n.s.
Prothrombin percent activity	-0.248	0.017
AFP	0.231	0.040
DCP	0.084	n.s.

AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BTR, branched-chain amino acids to tyrosine ratio; DCP, des- γ -carboxy prothrombin; MCV, mean corpuscular volume; MCHC, mean corpuscular hemoglobin concentration; n.s., not significant.

DISCUSSION

Our study demonstrated two important findings. First, serum vitamin B₁₂ levels were significantly elevated in patients categorized as Child-Pugh C and with primary liver cancer. Second, serum vitamin B₁₂ level was a significant independent predictor for overall survival in patients with chronic viral liver disease.

We found that serum vitamin B₁₂ levels were significantly higher in cirrhotic patients with Child-Pugh C than in patients with chronic hepatitis or Child-Pugh A/B cirrhosis. It has been previously reported that highly elevated vitamin B₁₂ levels in plasma were indicated in acute hepatitis, severe alcoholic liver disease, and cirrhosis.^{2-6, 11, 12} Our data indicate that serum vitamin B₁₂ levels were falsely elevated with the severity also in chronic viral liver disease. Total serum vitamin B₁₂ levels were




Fig. 2. Percentage of holoTC II and holoHC. **A:** Percentage of holoTC II was significantly different between Child-Pugh A and B ($P = 0.031$). $*P < 0.05$. **B:** The percentage of holoHC [(total vitamin B₁₂ – holoTC II) \times 100] was significantly higher in Child-Pugh B and C 86 (80–87)% than chronic hepatitis (CH) and Child-Pugh A 77 (31–89)% ($P = 0.006$). $**P < 0.01$. holoHC, holohaptocorrin; holoTC, holotranscobalamin.




Fig. 3. Cumulative survival rate calculated by the Kaplan-Meier method, by serum vitamin B₁₂ level quartiles.

A: The 90 patients were divided into quartiles by vitamin B₁₂ level: < 403.25 (Q1, solid line); 403.25–582 (Q2, dotted line), 583–879 (Q3, dashed line), and ≥ 880 pg/mL (Q4, dash-dotted line).

B: Cumulative survival rate differed between Q 1-3 (solid line) and Q4 (dotted line) in all the patients ($P = 0.058$). **C:** Cumulative survival rate differed significantly between Q 1-3 (solid line) and Q 4 (dotted line) in the patients without primary liver cancer ($P = 0.003$).

Table 6. Univariate and multivariate analyses of factors predicting the overall survival rate

Factors	Univariate <i>P</i> value	Multivariate analysis			
		HR	95% CI	<i>P</i> value	
Sex	0.374				
Age	year	0.369			
Albumin	g/dL	< 0.001	0.368	0.176–0.767	0.008
Total bilirubin	mg/dL	0.006	1.231	0.915–1.658	0.170
PT	%	0.086	1.010	0.984–1.036	0.457
AFP	> 10 ng/mL	0.003	1.546	0.632–3.781	0.340
DCP	> 40 AU/mL	< 0.001	2.682	1.084–6.636	0.033
Serum vitamin B ₁₂	pg/mL	0.034	1.001	1.000–1.001	0.029

CH, chronic hepatitis; AFP, alpha fetoprotein; CI, confidence interval; DCP, des- γ -carboxy prothrombin; HR, hazard ratio; PT, prothrombin percent activity.




Fig. 4. Scheme of the hypothesis for falsely elevated vitamin B₁₂ in liver disease.

HoloHC (■), the inactive form of vitamin B₁₂, is stored in the liver. The stored holoHC adjusts holoTC II(▲), the inactive form of vitamin B₁₂, in circulation. There are possible two mechanisms responsible for falsely elevated serum vitamin B₁₂ levels in liver diseases. First, holoHC leaks into the circulation due to the destruction of hepatocytes (excess release hypothesis). Second, the reduced uptake of holoHC by the injured liver (reduced clearance hypothesis). holoHC, holohaptocorrin; holoTC, holotranscobalamin.

significantly higher in cirrhotic patients. The biomarker of hepatic reserve, such as prothrombin activity percentage, was found to be weakly correlated with the total serum vitamin B₁₂ levels in the present study.

Among the patients with primary liver cancer, the vitamin B₁₂ level was higher in alcohol consumption ≥ 20 g/day group than in those were not. Alcoholic liver disease have already shown to have the falsely high vitamin B₁₂ levels associated with liver dysfunction.^{4,5} On the other hand, among the patients without primary liver cancer, serum vitamin B₁₂ levels were significantly higher in HBV than those in HCV patients. The reason was the number of patients classified into Child-Pugh B and C was significantly higher in HBV patients without primary liver cancer (data not shown).

Total serum vitamin B₁₂ levels were also significantly higher in patients with primary liver cancer than those without. Some reports have also indicated that serum vitamin B₁₂ levels are elevated in patients with HCC.^{13–15} However, primary liver cancer is usually complicated with viral cirrhosis, the elevation should be distinguished from the association with cirrhosis. In present study, the difference was demonstrated only in patients with chronic hepatitis. Therefore, it could be concluded that primary liver cancer directly associated with serum vitamin B₁₂ levels.

According to these findings, we could demonstrate that severe liver dysfunction (Child-Pugh C) and primary liver cancer affected the falsely elevated vitamin B₁₂ levels.

In this study, we analyzed holoTC II additionally in some patients to clarify the mechanisms of falsely elevation. Unfortunately, we could evaluate only one patient in Child-Pugh C. We observed significantly lower level (within normal range) of the holoTC II percentage in patients of Child-Pugh B and C. It also means the percentage of holoHC increased in Child-Pugh B and C.

Thus, we propose two mechanisms responsible for elevated serum vitamin B₁₂ levels in these patients (Fig. 4). First, holoHC possibly leaks into the circulation due to the destruction of hepatocytes (excess release hypothesis). This is supported by the observation that plasma vitamin B₁₂ levels are elevated in 25–40% cases of acute hepatitis.^{2, 11, 16, 17} However, in our study, serum vitamin B₁₂ levels did not correlate with transaminase levels, this hypothesis could not explain high serum vitamin B₁₂ in chronic viral hepatitis. Alternatively, the reduced uptake of holoHC by the injured liver may contribute to elevated levels of serum vitamin B₁₂ (reduced clearance hypothesis). The asialoglycoprotein receptors, which bind holoHC for uptake into the liver, are expressed on normal hepatocytes. Since the number of receptors decreases

with the destruction of hepatocytes or the progression of liver cancer, holoHC remains in the circulation.^{14, 15} The study using liver biopsy specimens have shown that the loss of vitamin B₁₂ storage in the liver is associated with increased serum vitamin B₁₂ levels.^{16, 18–21}

In our study, elevated levels of serum vitamin B₁₂ were also associated with poor prognosis. Some reports have already indicated that vitamin B₁₂ levels are associated with increased mortality in critically ill patients of other diseases.^{22, 23} The mechanisms that affect the prognosis of such patients remain unknown; however, based on the known aspects of hepatic inflammation and oxidative stress, it is possible to speculate on the mechanism. Previous reports have also shown that vitamin B₁₂ modulates inflammation. The relationship between vitamin B₁₂ and cytokine levels was demonstrated in humans.²⁴ In the report, vitamin B₁₂ deficiency was related to high levels of tumor necrosis factor- α (TNF- α), and vitamin B₁₂ supplementation normalized these levels. TNF- α is a well-known cytokine that plays a crucial role in chronic inflammation as well as in chronic hepatitis.^{25, 26} Another report has indicated that vitamin B₁₂ may regulate nuclear factor kappa B (NF κ B), which is transcription regulator activated by cytokines like TNF- α , and it determines cell survival and apoptosis.^{27, 28} These reports suggest that vitamin B₁₂ plays the role of a modulator for cytokine expression in the injured liver where the vitamin B₁₂ storage has diminished.

Tamura et al. also indicated the role of vitamin B₁₂ as an immunomodulator.²⁹ demonstrating that vitamin B₁₂ administration increased the percentages of cluster of differentiation (CD) 8⁺ cells and natural killer (NK) cells in vitamin B₁₂-deficient patients. Moreover, Birch et al. reported thiolatocobalamin (a vitamin B₁₂ derivative) has a protective effect on oxidant-damaged cells.³⁰ Furthermore, the hepatoprotective effect of vitamin B₁₂ has been demonstrated using dimethylnitrosamine-induced liver injury in a mouse model.³¹ This hepatoprotective effect of vitamin B₁₂ may be achieved by the maintenance of sulfhydryl levels under oxidative conditions.

Taken all things together, the association of falsely elevated vitamin B₁₂ with prognosis is considered to be due to diminished hepatic storage (excess release or reduced clearance) and loss of its hepatoprotective effect.

However, it remains unclear whether the hepatic vitamin B₁₂ storage has any effect on maintain hepatic function in normal liver. The efficacy of vitamin B₁₂ supplementation for cirrhosis also remains unknown. Further studies are needed to clarify the role of vitamin B₁₂ in hepatic diseases.

A limitation of our study is the small number of patients. The prognosis of Q4 (vitamin B₁₂ \geq 880 pg/mL)

was significantly poor only in the patients without primary liver cancer; however, primary liver cancer is usually complicated with cirrhosis. To predict the prognosis of viral liver disease, appropriate cut-off level should be determined in all the patients. Large-scale study should be conducted to clarify the cut-off level of serum vitamin B₁₂ for viral liver disease.

In conclusion, falsely elevated serum vitamin B₁₂ levels mainly composed of its increased holoHC were associated with severity and prognosis in viral liver disease.

Acknowledgments: We would like to thank Younghee Koh of Abbott Japan Co. Ltd. for technical support and Yuki Fujiwara of the laboratory department in Tottori University Hospital for technical assistance.

The authors declare no conflict of interest.

REFERENCES

- Herrmann W, Obeid R, Schorr H, Geisel J. Functional vitamin B12 deficiency and determination of holotranscobalamin in populations at risk. *Clin Chem Lab Med.* 2003;41:1478-88. PMID: 14656029.
- Ermens AA, Vlasveld LT, Lindemans J. Significance of elevated cobalamin (vitamin B12) levels in blood. *Clin Biochem.* 2003;36:585-90. PMID: 14636871.
- Solomon LR. Disorders of cobalamin (vitamin B12) metabolism: emerging concepts in pathophysiology, diagnosis and treatment. *Blood Rev.* 2007;21:113-30. PMID: 16814909.
- Baker H, Leevy CB, DeAngelis B, Frank O, Baker ER. Cobalamin (vitamin B12) and holotranscobalamin changes in plasma and liver tissue in alcoholics with liver disease. *J Am Coll Nutr.* 1998;17:235-8. PMID: 9627908.
- Djalali M, Champigneulle B, Guéant JL, el Kholty S, Gérard P, Nicolas JP. Increased serum corrinoids correlates with disease severity and IgA levels in alcoholic cirrhosis. *Digestion.* 1988;41:215-22. PMID: 3243381.
- Holdsworth CD, Atkinson M, Dossett JA, Hall R. An assessment of the diagnostic and prognostic value of serum vitamin B12 levels in liver disease. 1964;5:601-6. PMID: 14244040.
- Refsum H, Johnston C, Guttormsen AB, Nexø E. Holotranscobalamin and total transcobalamin in human plasma: determination, determinants, and reference values in healthy adults. *Clin Chem.* 2006;52:129-37. PMID: 16239338.
- Brada N, Gordon MM, Wen J, Alpers DH. Transfer of cobalamin from intrinsic factor to transcobalamin II. *J Nutr Biochem.* 2001;12:200-6. PMID: 11287214.
- Dou J, Xu W, Ye B, Zhang Y, Mao W. Serum vitamin B12 levels as indicators of disease severity and mortality of patients with acute-on-chronic liver failure. *Clin Chim Acta.* 2012;413:1809-12. PMID: 22814196.
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg.* 1973;60:646-9. PMID: 4541913.
- Arekul S, Panatampon P, Doungbarn J. Vitamin B12 and vitamin B12 binding proteins in liver diseases. *Southeast Asian J Trop Med Public Health.* 1977;8:322-8. PMID: 607423.

- 12 Goel A, Ramakrishna B, Muliyl J, Madhu K, Sajith KG, Zachariah U, et al. Use of serum vitamin B₁₂ level as a marker to differentiate idiopathic noncirrhotic intrahepatic portal hypertension from cryptogenic cirrhosis. *Dig Dis Sci* 2013;58:179-87. PMID: 22918688.
- 13 Lin CY, Kuo CS, Lu CL, Wu MY, Huang RF. Elevated serum vitamin B(12) levels in association with tumor markers as the prognostic factors predictive for poor survival in patients with hepatocellular carcinoma. *Nutr Cancer*. 2010;62:190-7. PMID: 20099193.
- 14 Osifo BO, Ayoola A, Parmentier Y, Gerard P, Nicolas JP. Correlation between serum enzymes and serum unsaturated vitamin B₁₂ binding proteins in primary liver carcinoma. *Enzyme* 1988;39:161-6. PMID: 2837386.
- 15 Frémont S, Champigneulle B, Gérard P, Felden F, Lambert D, Guéant JL, et al. Blood transcobalamin levels in malignant hepatoma. *Tumor Biol* 1991;12:353-9. PMID: 1724707.
- 16 Nelson RS, Doctor VM. Hepatic and serum vitamin B₁₂ content in liver disease. *Gastroenterology*. 1960;38:188-93. PMID: 14426484.
- 17 Hagelskjaer L, Rasmussen K. Methylmalonic acid concentration in serum not affected in hepatic disease. *Clin Chem*. 1992;38:493-5. PMID: 1568312.
- 18 Nelson RS, Doctor VM. Vitamin B₁₂ content of liver and serum in malignant neoplasia. *Gastroenterology*. 1962;42:414-8. PMID: 14478940.
- 19 Nelson RS, Doctor VM. Hepatic and serum vitamin B₁₂ in acute and chronic hepatitis. *South Med J*. 1964;57:1432-6. PMID: 14226906.
- 20 Joske RA. The vitamin B₁₂ content of human liver tissue obtained by aspiration biopsy. *Gut*. 1963;4:231-5. PMID: 14058264.
- 21 Kanazawa S, Herbert V. Total corrinoid, cobalamin (vitamin B₁₂), and cobalamin analogue levels may be normal in serum despite cobalamin in liver depletion in patients with alcoholism. *Lab Invest*. 1985;53:108-10. PMID: 4010227.
- 22 Geissbühler P, Mermillod B, Rapin CH. Elevated serum vitamin B₁₂ levels associated with CRP as a predictive factor of mortality in palliative care cancer patients: a prospective study over five years. *J Pain Symptom Manage*. 2000;20:93-103. PMID: 10989247.
- 23 Svirid S, Khalaila R, Daher S, Bayya A, Linton DM, Stav I, et al. Increased Vitamin B₁₂ levels are associated with mortality in critically ill medical patients. *Clin Nutr*. 2012;31:53-9. PMID: 21899932.
- 24 Peracchi M, Bamonti Catena F, Pomati M, De Franceschi M, Scalabrino G. Human cobalamin deficiency: alterations in serum tumour necrosis factor-alpha and epidermal growth factor. *Eur J Haematol*. 2001;67:123-7. PMID: 11722601.
- 25 Yoshioka K, Kakumu S, Arai M, Tsutsumi Y, Inoue M, Wakita T, et al. Immunohistochemical studies of intrahepatic tumour necrosis factor alpha in chronic liver disease. *J Clin Pathol*. 1990;43:298-302. PMID: 1692847.
- 26 Yoshioka K, Kakumu S, Arai M, Tsutsumi Y, Inoue M. Tumour necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. *Hepatology*. 1989;10:769-73. PMID: 2553575.
- 27 Wheatley C. A scarlet pimpernel for the resolution of inflammation? The role of supra-therapeutic doses of cobalamin, in the treatment of systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic or traumatic shock. *Med Hypotheses*. 2006;67:124-42. PMID: 16545917.
- 28 Kirillova I, Chaisson M, Fausto N. Tumour necrosis factor induces DNA replication in hepatic cells through nuclear factor kappaB activation. *Cell Growth Differ*. 1999;10:819-28. PMID: 10616907.
- 29 Tamura J, Kubota K, Murakami H, Sawamura M, Matsushima T, Tamura T, et al. Immunomodulation by vitamin B₁₂: augmentation of CD8+ T lymphocytes and natural killer (NK) cell activity in vitamin B₁₂-deficient patients by methyl-B₁₂ treatment. *Clin Exp Immunol*. 1999;116:28-32. PMID: 10209501.
- 30 Birch CS, Brasch NE, McCaddon A, Williams JH. A novel role for vitamin B(12): Cobalamins are intracellular antioxidants in vitro. *Free Radic Biol Med*. 2009;47:184-8. PMID: 19409980.
- 31 Isoda K, Kagaya N, Akamatsu S, Hayashi S, Tamesada M, Watanabe A, et al. Hepatoprotective effect of vitamin B₁₂ on dimethylnitrosamine-induced liver injury. *Biol Pharm Bull*. 2008;31:309-11. PMID: 18239293.